GeneThera (GeneThera) Forward Dividend Yield % : 0.00% (As of May. 23, 2024)

View and export this data going back to 2000. Start your Free Trial

What is GeneThera Forward Dividend Yield %?

As of today (2024-05-23), the Forward Annual Dividend Yield of GeneThera is 0.00%.

As of today (2024-05-23), the Trailing Annual Dividend Yield of GeneThera is 0.00%.

GTHR's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.585
* Ranked among companies with meaningful Forward Dividend Yield % only.

GeneThera's Dividends per Share for the three months ended in Sep. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of GeneThera's Forward Dividend Yield %

For the Biotechnology subindustry, GeneThera's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeneThera's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneThera's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where GeneThera's Forward Dividend Yield % falls into.

GeneThera Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

GeneThera (OTCPK:GTHR) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

GeneThera Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of GeneThera's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneThera (GeneThera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035

Website

http://genetherainc.com

GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.

Executives

Avel Kolesnikov	director	11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr	10 percent owner	632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd	10 percent owner	CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner	director, officer: Chief Financial Officer	728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici	director, 10 percent owner, officer: Chief Executive Officer	3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry	director, 10 percent owner, officer: Chief Administative Officer	11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines